Clinical response at Day 3 of therapy and economic outcomes in hospitalized patients with acute bacterial skin and skin structure infection (ABSSSI)

Current Medical Research and Opinion

Volumn 29, Issue 7, 2013, Pages 869-877

  Amara, Shilpa ^a   Adamson, Robert T ^a   Lew, Indu ^a   Huang, Xingyue ^b  

^a Barnabas Health   (United States)

^b FOREST RESEARCH INSTITUTE   (United States)

Author keywords

Acute bacterial skin and skin structure infection; Cellulitis; Clinical response; Wound infection

Indexed keywords

CEFAZOLIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; VANCOMYCIN;

ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTION; ADULT; AGED; ANTIBIOTIC THERAPY; BACTERIAL SKIN DISEASE; CELLULITIS; COHORT ANALYSIS; CONTROLLED STUDY; ERYSIPELAS; FEMALE; HOSPITAL PATIENT; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; RETROSPECTIVE STUDY; REVIEW; SKIN ABSCESS; TEMPERATURE; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; UNITED STATES; WOUND INFECTION;

AGED; AMPICILLIN; ANTI-BACTERIAL AGENTS; CEFAZOLIN; FEMALE; HOSPITALIZATION; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; PENICILLANIC ACID; PIPERACILLIN; RETROSPECTIVE STUDIES; SKIN DISEASES, BACTERIAL; SKIN DISEASES, INFECTIOUS; SULBACTAM; TREATMENT OUTCOME; VANCOMYCIN;

EID: 84880314298     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.803056     Document Type: Review

References (8)

1. Guidance for Industry: Acute Bacterial Skin and Skin Structure Infections: Developing Drugs for Treatment. Draft Guidance, August 2010. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Available at: http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071185.pdf [Last accessed 30 May 2012]
2. Nichols RL. Optimal treatment of complicated skin and skin structure infections. J Antimicrob Chemother 1999;44:19-23
3. Teflaro [package insert]. St. Louis, MO: Forest Pharmaceuticals Inc., 2010
4. Corey GR, Wilox M, Talbot GH, et al. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis 2010;51:641-50
5. Hatoum HT, Akhras KS, Lin SJ. The attributable clinical and economic burden of skin and skin structure infections in hospitalized patients: a matched cohort study. Diagn Microbiol Infect Dis 2009;64:305-10
6. Hernandez PO, Lema S, Tyring SK, et al. Ceftaroline in complicated skin and skin-structure infections. Infect Drug Resist 2010;5:23-35
7. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005;41:1373-406
8. Edelsberg J, Berger A, Weber DJ, et al. Clinical and economic consequences of failure of initial antibiotic therapy for hospitalized patients with complicated skin and skin-structure infections. Infect Control Hosp Epidemiol 2008;29:160-9